NeOnc Technologies Holdings, Inc. entered into a fourth Securities Purchase Agreement on April 20, 2026, issuing 277,777 shares of common stock and warrants to one investor for approximately $2 million to fund NEO216 preclinical trials.
Key takeaways
Entered fourth Securities Purchase Agreement on April 20, 2026, for up to 406,694 shares at $7.20/share and warrants at $9.00 exercise price.
Initial closing issued 277,777 shares and warrants to one investor for ~$2M; offering terminates April 30, 2026.
Net proceeds to fund NEO216 preclinical trials.
Securities issued under Section 4(a)(2) exemption; resale registration to be filed within 10 days of initial closing.
Previously disclosed three prior agreements issued total 1,813,538 shares for ~$13.07M.